5篇
您的检索式：作者名="Stephan E.Baldus"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis显示文摘AIM: To evaluate the role of CDX2 homeobox protein as a predictor for cancer progression and prognosis as well as its correlation with MUC2 expression. CDX2 represents a transcription factor for various intestinal genes (including MUC2) and thus an important regulator of intestinal differentiation, which could previously be identified in gastric carcinomas and intestinal metaplasia.METHODS: Formalin-fixed and paraffin-embedded tissues from 190 gastric carcinoma patients were stained with monodonal antibodies recognizing CDX2 and MUC2, respectively. Immunoreactivity was evaluated semiquantitatively and statistical analyses including χ2 tests, uni- and multi-variate survival analyses were performed.RESULTS: CDX2 was mostly expressed in a nuclear or supranuclear pattern, whereas MUC2 showed an almost exclusive supranuclear reactivity. Both antigens were present in >80% of areas exhibiting intestinal metaplasia. An immunoreactivity in >5% of the tumor area was observed in 57% (CDX2) or in 21% (MUC2) of the carcinomas. The presence of both molecules did not correlate with WHO,significantly stronger vlUC2 expression in mucinous tumors). CDX2 correlated with a lower pT and pN stage in the subgroups of intestinal and stage I cancers and was associated with MUC2 positivity. A prognostic impact of CDX2 or MUC2 was not observed. CONCLUSION: CDX2 and MUC2 play an important role in the differentiation of normal, inflamed, and neoplastic gastric tissues. According to our results, loss of CDX2 may represent a marker of tumor progression in early gastric cancer and carcinomas with an intestinal phenotype. | Kristina Roessler Stefan P.M(o|¨)nig Paul M.Schneider Franz-Georg Hanisch Stephanie Landsberg Juergen Thiele Arnulf H.H(o|¨)lscher Hans P.Dienes Stephan E.Baldus | 2005 | World Journal of Gastroenterology2005，11，21： | 15 |
| 2 | Staging of esophageal carcinoma: Length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?显示文摘 | ElfriedeBollschweiler Stephan E.Baldus WolfgangSchr?der Paul M.Schneider Arnulf H.H?lscher | 2006 | J Surg Oncol2006，，5： | 1 |
| 3 | Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma显示文摘 | UdoRoth HaniehRazawi JuliaHommer KatjaEngelmann TiloSchwientek StefanMüller Stephan E.Baldus GeorgiosPatsos Anthony P.Corfield ChristosParaskeva Franz‐GeorgHanisch | 2010 | Proteomics2010，，2： | 1 |
| 4 | Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma显示文摘 | UdoRoth HaniehRazawi JuliaHommer KatjaEngelmann TiloSchwientek StefanMüller Stephan E.Baldus GeorgiosPatsos Anthony P.Corfield ChristosParaskeva Franz‐GeorgHanisch | 2010 | Proteomics2010，，2： | 1 |
| 5 | Monitoring of Tumor Response to Neoadjuvant Radio-Chemotherapy of Esophageal Carcinoma by F-18-FDG-PET显示文摘Introduction: For clinical assessment of neoadjuvant radiochemotherapy of esophageal cancer reliable in-vivo methods are necessary. Therefore, the capabilities of F-18-Fluorodesoxyglucose-PET in comparison to histomorphological grading of tumor regression were studied. Methods: In 33 patients with locally advanced esophageal carcinoma (uT3, uN0-1, cM0) F-18-FDG-PET was performed before and 2 weeks after radiochemotherapy. All tumors were resected by transthoracic en-bloc esophagectomy 3–4 weeks after induction therapy. A subgroup of 11 patients underwent weekly PET scan during neoadjuvant therapy. PET was performed in a dedicated scanner 1.3 h after administration of 370 MBq F-18-FDG. Data analysis based on maximum SUV data derived from individual regions of interest in pre- and posttherapeutic images. PET data were compared to histomorphological grading parameters for tumor regression whithin the resected tissues. Results: The comparison of histopathological tumor regression after neoadjuvant therapy and PET SUV di?erences showed a signi?cant χ2 P -value of 0.006. There was a signi?cant decrease 五笔字型计算机汉字输入技术 of the SUV data from 9.1±3.5 to 4.3±1.9 (P <0.0001). In therapy responders SUV was diminished by 59 % and in non-responders by 34 %. Longitudinal SUV measurement during neoadjuvant therapy showed a strong SUV decrease already after one and two weeks (P =0.021 and 0.003). Conclusion: The recent data of the FDG-PET follow-up after neoadjuvant therapy show that PET is able to predict therapy response. Longitudinal PET data advocate that it may be possible to recognize response also very early during radiochemotherapy. | Peter Theissen Paul M.Schneider Stephan E.Baldus Alexandra Jost Markus Dietlein Rolf P.Muller Arnulf H.Holscher Harald Schicha | 2004 | The Chinese-German Journal of Clinical Oncology2004，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员